Nanomedicines are innovative and promising, but lack a convincing clinical presence. Thus,
biomimetic nanoparticles (BMNPs) have been designed with functionalizations which …

Metastatic recurrence and postoperative wound infection are two major challenges for
breast cancer patients. In this study, a multifunctional responsive hydrogel system was …

Simple Summary Breast cancer (BC) is the most common malignant neoplasm in women
and one of the leading causes of cancer death in women worldwide. Programmed death …

Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …

Background Approximately 80% of all breast cancers (BCs) are currently categorized as
human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0 …

Importance ERBB2-low (ie, ERBB2immunohistochemistry score of 1+ or 2+ in the absence
ofERBB2gene amplification) breast cancer (BC) is a new entity, with emerging dedicated …

Luminal breast cancers are hormone receptor (estrogen and/or progesterone) positive that
are further divided into HER2-negative luminal A and HER2-positive luminal B subtypes …

Cancer patients with advanced disease are characterized by intrinsic challenges in
predicting drug response patterns, often leading to ineffective treatment. Current clinical …

Antibody–drug conjugates (ADCs) are a class of antineoplastic agents whose structure is
composed of three main components: a monoclonal antibody (mAB) targeting a specific …

Breast cancer is still a lethal disease and the leading cause of death in women, undermining
patients' survival and quality of life. Modern techniques of surgery and radiotherapy allow for …